Advanced ovarian carcinoma: A prospectiv
β
J. Carmo-Pereira; F. Oliveira Costa; Elvira Henriques; J. Almeida Ricardo
π
Article
π
1981
π
John Wiley and Sons
π
English
β 367 KB
π 2 views
Fifty-seven evaluable patients with advanced ovarian carcinoma were randomized to receive either a combination of hexamethylmelamine, cyclophosphamide, methotrexate and 5-fluorouracil (Hexa-CAF) or high-dose cyclophosphamide alone given intravenously intermittently. Objective responses were seen in